Facilitating Rubraca delivery to your patients where and when they need it

The Rubraca (rucaparib) delivery model lets you choose from a network of specialty pharmacies and wholesalers.

For additional support, your patients may enroll in Rubraca Connections
Rubraca Connections and our network specialty pharmacies offer 5 key areas of patient support*:
Rubraca Connections Access Specialist
Rubraca Financial Assistance Programs
Rubraca delivery: specialty pharmacies/wholesalers
24/7 specialty pharmacy support
Simple enrollment process

To enroll a patient in Rubraca Connections, or if you have any questions or would like more information, please call 1-844-779-7707, Monday through Friday 8 AM to 8 PM EST, or visit RubracaConnections.com.

*Patients do not need to enroll in Rubraca Connections to receive Rubraca.
Please visit RubracaConnections.com for more information on Rubraca financial support programs.
Education and adherence support for patients is available only from network specialty pharmacies.

Keep me updated
BE AMONG THE FIRST TO RECEIVE NEWS AND UPDATES ABOUT RUBRACA.
*Required fields
SELECT IMPORTANT SAFETY INFORMATION
SELECT IMPORTANT SAFETY INFORMATION

Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) was reported in 2 of 377 (0.5%) patients with ovarian cancer treated with Rubraca. The duration of Rubraca treatment prior to the diagnosis of MDS/AML was 57 days and 539 days. Both patients received prior treatment with platinum and other DNA damaging agents.

AML was reported in 2 (< 1%) patients with ovarian cancer enrolled in a blinded, randomized trial evaluating Rubraca versus placebo. One case of AML was fatal. The duration of treatment prior to the diagnosis of AML was 107 days and 427 days. Both patients had received prior treatment with platinum and other DNA damaging agents.

Do not start Rubraca until patients have recovered from hematological toxicity caused by previous chemotherapy (≤ Grade 1).

Monitor complete blood count testing at baseline and monthly thereafter. For prolonged hematological toxicities, interrupt Rubraca and monitor blood counts weekly until recovery. If the levels have not recovered to Grade 1 or less after 4 weeks, refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue Rubraca.

Based on its mechanism of action and findings from animal studies, Rubraca can cause fetal harm when administered to a pregnant woman. Apprise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months following the last dose of Rubraca.

Most common adverse reactions (≥ 20%; Grade 1-4) were nausea (77%), asthenia/fatigue (77%), vomiting (46%), anemia (44%), constipation (40%), dysgeusia (39%), decreased appetite (39%), diarrhea (34%), abdominal pain (32%), dyspnea (21%), and thrombocytopenia (21%).

Most common laboratory abnormalities (≥ 35%; Grade 1-4) were increase in creatinine (92%), increase in alanine aminotransferase (ALT) (74%), increase in aspartate aminotransferase (AST) (73%), decrease in hemoglobin (67%), decrease in lymphocytes (45%), increase in cholesterol (40%), decrease in platelets (39%), and decrease in absolute neutrophil count (35%).

Because of the potential for serious adverse reactions in breast-fed infants from Rubraca, advise lactating women not to breastfeed during treatment with Rubraca and for 2 weeks after the final dose.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Clovis Oncology, Inc. at 1-844-258-7662.

Please see full Prescribing Information for additional Important Safety Information.